Introduction: What they say:
A study from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA has reported that “miR-34a blocks osteoporosis and bone metastasis by inhibiting osteoclastogenesis and Tgif2.”
This study was published in the June 25, 2014 Nature [I.F >42] by Prof. Wan Y, Krzeszinski and others from the Department of Pharmacology, The University of Texas Southwestern Medical Center, Dallas, Texas 75390, USA.
What we say:
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: RKIP inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene
From Research findings to Therapeutic utility:
RKIP, by up-regulating its target gene, it may suppress the expression of Tgif2. Thereby, it may inhibit the progression of Osteoporosis and bone metastasis.
Thus, pharmacological formulations encompassing “RKIP activators or RKIP activator plus any of the known compounds that are in use to treat osteoporosis” can be used to inhibit osteoporosis and bone metastasis.
Details of the research findings:
Idea Formulated (with experimental evidence) by: Dr L Boominathan PhD
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
For purchase & payment details, you may reach us at firstname.lastname@example.org
Citation: Boominathan, L., Molecular therapy for Bone disorders: Raf kinase Inhibitor Protein (RKIP) inhibits the expression of Tgif2 and suppresses osteoporosis and bone metastasis via up-regulation of its target gene, 5/February/2017, 11.20 pm., Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com